InterCure Ltd.
[PRESS RELEASE] – NEW YORK and HERZLIYA, Israel, June 15, 2026 – InterCure Ltd. announced the successful completion of the first tranche of its acquisition of Botanico Ltd., also known as ISHI, an Israeli cannabis technology and brand company.
- Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets.
- The Botanico transaction further strengthens InterCure’s portfolio through exclusive rights to a broad collection of award-winning American cannabis genetics, proprietary strains, premium brands and advanced production technologies.
- Through the Botanico transaction, InterCure gains access to ISHI’s advanced AI-driven technologies, automated production systems and exclusive strategic brand alliances with leading U.S. cannabis operators, including The Flowery.
- As part of the initial closing of the transaction, InterCure will issue 2,471,061 ordinary shares. Upon satisfaction of the conditions specified in the share purchase agreement, InterCure will issue an additional 2,470,073 ordinary shares.
- Earlier this year, InterCure reported its first meaningful revenues from the rapidly growing German medical cannabis market, supporting its strategy of building a leading international pharmaceutical cannabis platform.
- To support growing demand, InterCure has appointed a German management and sales team and anticipates multiple product launches in the second half of the year.
- The company’s evaluation of opportunities in the United States is focused exclusively on regulated medical cannabis markets.
Alexander Rabinovitch, CEO and chairman of InterCure, said, “The Botanico acquisition, German market momentum and evolving U.S. regulatory landscape support the company’s vision of building a leading international medical cannabis company serving patients across multiple regulated markets.”
